Shanghai Kehua Bio-engineering (002022.SZ): The hepatitis C virus (HCV) nucleic acid detection kit (PCR-fluorescence method) has obtained a medical device registration certificate.
Kehua Bio (002022.SZ) announced that its subsidiary, Suzhou Tianlong Biotechnology Co., Ltd., has recently...
Shanghai Kehua Bio-engineering (002022.SZ) announced that its holding subsidiary, Suzhou Tianlong Bio-technology Co., Ltd., has received a medical device registration certificate (in vitro diagnostic reagent) issued by the National Medical Products Administration. The product involved is the "Hepatitis C Virus (HCV) Nucleic Acid Detection Kit (PCR-fluorescence method)". This product is used for quantitatively detecting Hepatitis C Virus nucleic acid (RNA) in human serum or plasma samples.
Related Articles
.png)
A-share market opening express | Three major indexes rise and fall differently. Brain-computer interface sector leads in gains.
HK Stock Market Move | IMMUNEONCO-B(01541) increased by over 7% against the market trend, IMM2510/AXN-2510 received FDA approval for IND application.
HK Stock Market Move | CIRRUS (02507) fell by more than 7% at the beginning of trading. The controlling shareholder, China Aviation International Air, is selling approximately 4.78% of its shares in Hong Kong.
A-share market opening express | Three major indexes rise and fall differently. Brain-computer interface sector leads in gains.
HK Stock Market Move | IMMUNEONCO-B(01541) increased by over 7% against the market trend, IMM2510/AXN-2510 received FDA approval for IND application.
HK Stock Market Move | CIRRUS (02507) fell by more than 7% at the beginning of trading. The controlling shareholder, China Aviation International Air, is selling approximately 4.78% of its shares in Hong Kong.
